Contact this trialFirst, we need to learn more about you.
PARP Inhibitor
Olaparib + Cediranib for Ovarian Cancer
Recruiting2 awardsPhase 3
Toronto
This trial is testing two treatments for women with certain types of relapsed cancer who responded well to chemotherapy. One treatment uses two drugs to attack the cancer in different ways, while the other uses just one drug.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service